(NASDAQ:MRCY), Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $38.1 million with Free Cash Flow of $34.0 million, with record free […]

(NASDAQ:DRTS),(NASDAQ:DRTSW), – FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer – – Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot studies, positioned for imminent patient treatment initiation during the remainder of 2025 –

(NASDAQ:OLMA), Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025 Mature data from the Phase 1b/2 study

HighPeak Energy, Inc. Announces Second Quarter 2025 Financial and Operating Results GlobeNewswire August 11, 2025 FORT WORTH, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales volumes averaged approximately 48.6

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire August 11, 2025 Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction expected

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 11, 2025 – FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer – – Multiple U.S. clinical trials, including pancreatic cancer and

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights GlobeNewswire August 11, 2025 Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study

Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance GlobeNewswire August 11, 2025 ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three

Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results GlobeNewswire August 11, 2025 Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of

(NasdaqGM:HROW), Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by